TORONTO, ONTARIO -- (Marketwired) -- 10/19/17 -- Revive Therapeutics Ltd. ("Revive" or the "Company") (TSX VENTURE:…
Continue ReadingTag: revive-therapeutics-ltd
Revive Therapeutics Advances Research Program of Cannabinoid-Based Drug Delivery Technology for the Medical Marijuana and Pharmaceutical Markets
TORONTO, ONTARIO -- (Marketwired) -- 09/12/17 -- Revive Therapeutics Ltd. ("Revive" or the "Company") (TSX VENTURE:…
Continue ReadingRevive Therapeutics Appoints Dr. Arun Sanyal, MD, as Scientific Advisor for Cannabinoid-Based Therapeutics Targeting Liver Diseases
TORONTO, ONTARIO -- (Marketwired) -- 08/22/17 -- Revive Therapeutics Ltd. ("Revive" or the "Company") (TSX VENTURE:…
Continue ReadingRevive Therapeutics Ltd. Grants Incentive Stock Options
TORONTO, ONTARIO -- (Marketwired) -- 04/12/17 -- Revive Therapeutics Ltd. ("Revive" or the "Company") (TSX VENTURE:…
Continue ReadingRevive Therapeutics Appoints Dr. Scott Friedman, MD, as Scientific Advisor for Cannabinoid-Based Therapeutics Targeting Liver Diseases
TORONTO, ONTARIO -- (Marketwired) -- 03/22/17 -- Revive Therapeutics Ltd. ("Revive" or the "Company") (TSX VENTURE:…
Continue ReadingRevive Therapeutics Announces Initiation of a Phase 2 Study of REV-004 (Bucillamine) in Cystinuria
TORONTO, ONTARIO -- (Marketwired) -- 02/07/17 -- Revive Therapeutics Ltd. ("Revive" or the "Company") (TSX VENTURE:…
Continue ReadingRevive Therapeutics Appoints Dr. Pritesh Kumar as Scientific Advisor for Cannabinoid-Based Therapeutics
TORONTO, ONTARIO -- (Marketwired) -- 01/24/17 -- Revive Therapeutics Ltd. ("Revive" or the "Company") (TSX VENTURE:…
Continue ReadingRevive Therapeutics Engages NYU School of Medicine for Cystinuria Phase 2 Study
TORONTO, ONTARIO — (Marketwired) — 12/21/16 — Revive Therapeutics Ltd. (“Revive” or the “Company”) (TSX VENTURE:…
Continue ReadingRevive Therapeutics Ltd. Announces Results for the Three Months Ended September 30, 2014
TORONTO, ONTARIO -- (Marketwired) -- 11/26/14 -- Revive Therapeutics Ltd. (TSX VENTURE: RVV) ("Revive" or the…
Continue ReadingRevive Therapeutics Ltd. Announces US FDA Acceptance of IND to Commence Clinical Trial for Bucillamine for the Treatment of Gout
TORONTO, ONTARIO -- (Marketwired) -- 11/26/14 -- Revive Therapeutics Ltd. (TSX VENTURE: RVV) ("Revive" or the…
Continue Reading